Cobalt has advised Decathlon on a new lease agreement with Spice Home shopping center in Riga, Latvia. Azanda & Associates reportedly advised Spice Home.
Cobalt Advises Bauhub on Sale to Tocoman
Cobalt has advised the shareholders of Bauhub on its sale to Admicom's subsidiary Tocoman.
Cobalt Advises PSA on Acquisition of Parnu Sadam from Transcom
Cobalt has advised PSA on its acquisition of 50% of Parnu Sadam shares from Transcom.
Eversheds Sutherland and Cobalt Advise on Sale of Meditec AB and Medicloud to Everfield
Eversheds Sutherland has advised Everfield on its acquisition of Meditec AB and Medicloud SIA. Cobalt advised the sellers.
Cobalt Advises Latvenergo on Acquisition of DSE Aizpute Solar
Cobalt has advised Latvenergo on its acquisition of DSE Aizpute Solar from developer Danish Sun Energy ApS. Sorainen reportedly advised the sellers.
TGS Baltic Advises Simpact Ventures on Investment in Ligence
TGS Baltic has advised Simpact Ventures on its investment in Ligence as part of a round that also saw the participation of Coinvest Capital, the European Innovation Council, Estonian venture capital firm Lemonade Stand, the NGL business angel syndicate, and private investor Rita Sakus.
TGS Baltic and Cobalt Advise on AirBaltic's EUR 40 Million Issuance
TGS Baltic, working with Linklaters, has advised sole bookrunner Citigroup Global Markets Europe on the tap issue of EUR 40 million 14.50% senior secured bonds by the Latvian national airline AirBaltic. Cobalt, working with Dentons, advised AirBaltic.
Cobalt and Ellex Advise on Printify's Merger with Printful
Cobalt, working with Cooley, has advised Printify on its merger with Printful. Ellex, working with Latham & Watkins, advised Printful.
Cobalt Advises Consolis on Agreement with Nordex for Wind Turbine Tower Manufacturing
Cobalt has advised Consolis Latvia on a partnership agreement with the Nordex Group.
Corporate Liability When Raising Funds on the Capital Market in Latvia
Raising funds on the capital market—through the issuance of shares or bonds—provides companies with substantial advantages. Obtaining funds through capital market not only facilitates diversification of financial portfolios and reduces dependence on bank financing but also conveys a strong message to the issuer’s customers and business partners, illustrating the commitment to high standards of corporate governance. At the same time, by ensuring that the company’s securities are publicly listed, its members of the management board take responsibility towards the company itself, the shareholders, and other investors.
Cobalt Advises 15min on EUR 16 Million Bond Issue Placement
Cobalt has advised the 15min group on its placement of a EUR 16 million bond issue.
Cobalt Advises Devbridge Foundation on Kaunas Sobor Lighting Project
Cobalt has advised the Devbridge Foundation on the completion and transfer of the Kaunas Sobor lighting project to the Kaunas City Municipality.
Cobalt Advises on Sugihara House Museum on Setting up Tangible Capital Fund
Cobalt has advised Sugihara House Museum on setting up the Tangible Capital Fund.
Cobalt Advises EBRD on EUR 100 Million Investment in Green Genius
Cobalt has advised the EBRD on a EUR 100 million investment in Green Genius.
Cobalt and Noor Advise on Ovoko's EUR 20 Million Investment Round
Cobalt has advised Ovoko on a EUR 20 million phase B venture capital investment round led by Smash Capital. Noor advised the founders of Ovko. Sorainen reportedly advised Smash Capital.
Cobalt Advises Change Ventures on Investment in Certific
Cobalt has advised Change Ventures on co-leading a EUR 700,000 round for Certific, alongside Firstpick and Heartfelt VC.
Latvia: Further Solutions to Drug Availability and Monitoring Problems
Following extensive discussions between industry stakeholders and state institutions, several crucial solutions have been identified to address the problems of drug availability and monitoring control. The primary aim is to ensure wider and faster access to medicinal products for patients in Latvia.
Estonia: Pharma Disputes – Weak Patents May Cost Originators Heavily in Disputes with Generics
It is not new that originator pharmaceutical companies try to block generic competitors from entering the market. Considering the recent developments in the Court of Justice of the European Union (CJEU), originators should tread carefully when defending their patents. Having a strong patent is crucial, and the consequences of failing to vet the strength of a patent could end up costly.